75/100BCardinal Health stock forecast 2027–2031
Analysts' average 12-month price target for Cardinal Health is 279.33, 2.8% above the current price of 271.74. Their targets range from 265.00 to 295.00.
Of the 12 firms that rated Cardinal Health in the past 12 months, 11 rate it buy or strong buy, 1 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 265.00 to 295.00, with an average of 279.33.
| Strong buy | 0 | |
| Buy | 11 | |
| Hold | 1 | |
| Sell | 0 | |
| Strong sell | 0 |
12-month price target
| Highest target | 295.00 |
| Average target | 279.33 |
| Lowest target | 265.00 |
| Current price | 271.74 |
Cardinal Health price target history
Have analysts recently raised or lowered their Cardinal Health price target and rating?
How analysts rate Cardinal Health, month by month
11 of 12 firms rate it buy now, against 10 of 12 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Cardinal Health analyst upgrades, downgrades and price targets
The latest rating change came on 9 January 2026, when Citigroup upgraded Cardinal Health from Neutral to Buy. The most recent new target came from Mizuho Securities on 5 November 2026: 290.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 5 Nov 2026 | Mizuho Securities Steven Valiquette | — | 280.00 → 290.00 | +3.6% | 267.82 |
| 20 Oct 2026 | Mizuho Securities | Reiterated · Outperform | 250.00 → 280.00 | +12.0% | 252.65 |
| 16 Oct 2026 | UBS Kevin Caliendo | Reiterated · Buy | 280.00 → 295.00 | +5.4% | 253.71 |
| 19 Aug 2026 | RBC Capital Ryan Halsted | — | 276.00 | — | 234.98 |
| 13 Aug 2026 | Barclays | Reiterated · Overweight | 258.00 → 275.00 | +6.6% | 234.16 |
| 12 Aug 2026 | Morgan Stanley | Reiterated · Overweight | 255.00 → 265.00 | +3.9% | 236.64 |
| 12 Aug 2026 | Evercore ISI | Reiterated · Outperform | 240.00 → 270.00 | +12.5% | 240.26 |
| 12 Aug 2026 | UBS | Reiterated · Buy | 274.00 → 280.00 | +2.2% | 240.26 |
| 12 Aug 2026 | Wells Fargo Stephen Baxter | Reiterated · Overweight | 256.00 → 277.00 | +8.2% | 240.26 |
| 12 Aug 2026 | Mizuho Securities Steven Valiquette | Reiterated · Outperform | 235.00 → 250.00 | +6.4% | 240.26 |
| 12 Aug 2026 | Robert W. Baird Eric Coldwell | — | 248.00 → 274.00 | +10.5% | 240.26 |
| 11 Aug 2026 | Leerink Partners | — | 275.00 → 292.00 | +6.2% | 240.26 |
| 20 Jul 2026 | UBS | Reiterated · Buy | 260.00 → 274.00 | +5.4% | 226.42 |
| 1 May 2026 | Robert W. Baird | — | 252.00 → 248.00 | -1.6% | 195.08 |
| 8 Apr 2026 | Evercore ISI Elizabeth Anderson | Reiterated · Outperform | 260.00 → 240.00 | -7.7% | 215.13 |
| 9 Mar 2026 | Leerink Partners Michael Cherny | — | 240.00 → 275.00 | +14.6% | 222.28 |
| 24 Feb 2026 | Barclays | Reiterated · Overweight | 243.00 → 258.00 | +6.2% | 224.82 |
| 10 Feb 2026 | Wells Fargo | Reiterated · Overweight | 179.00 → 256.00 | +43.0% | 225.76 |
| 6 Feb 2026 | Morgan Stanley | — | 245.00 → 255.00 | +4.1% | 229.63 |
| 6 Feb 2026 | Robert W. Baird | — | 250.00 → 252.00 | +0.8% | 228.78 |
| 6 Feb 2026 | UBS Kevin Caliendo | — | 220.00 → 260.00 | +18.2% | 228.63 |
| 6 Feb 2026 | Mizuho Securities Steven Valiquette | Reiterated · Outperform | 222.00 → 235.00 | +5.9% | 227.18 |
| 5 Feb 2026 | Evercore ISI Elizabeth Anderson | — | 220.00 → 260.00 | +18.2% | 227.18 |
| 29 Jan 2026 | Morgan Stanley Erin Wright | Reiterated · Overweight | 181.00 → 245.00 | +35.4% | 210.39 |
| 14 Jan 2026 | Robert W. Baird Eric Coldwell | — | 232.00 → 250.00 | +7.8% | 211.98 |
| 13 Jan 2026 | Leerink Partners Michael Cherny | — | 186.00 → 240.00 | +29.0% | 208.24 |
| 12 Jan 2026 | Mizuho Securities Steven Valiquette | — | 210.00 → 222.00 | +5.7% | 201.11 |
| 9 Jan 2026 | Citigroup | Upgraded · Neutral → Buy | — | — | — |
| 8 Dec 2025 | Barclays Glen Santangelo | — | 243.00 | — | 198.88 |
Cardinal Health EPS and revenue estimates
Analysts expect Cardinal Health's EPS to grow 29.2% a year until 2029. Over the last 5 years it grew 28.3% a year, and over the last 3 years 79.0%.
Analysts expect Cardinal Health's revenue to grow 5.4% a year until 2029. Over the last 5 years it grew 9.4% a year, and over the last 3 years 7.4%.
Revenue
EPS
Does Cardinal Health beat earnings estimates?
On average, analysts' EPS estimate was 11.5% off the result, either way, and their revenue estimate 2.0%, over the last 12 quarters.
- EPS beats
- 96 / 136
- Revenue beats
- 87 / 120
- Average EPS surprise, last 12
- +11.5%
- Since
- January 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 5 Nov 2026 | 2.94 | 3.26 | +10.9% | 66.67B | 67.51B | +1.3% |
| Q4 FY2026 | 11 Aug 2026 | 2.42 | 2.91 | +20.2% | 65.15B | 63.67B | -2.3% |
| Q3 FY2026 | 30 Apr 2026 | 2.79 | 3.17 | +13.6% | 62.10B | 60.94B | -1.9% |
| Q2 FY2026 | 5 Feb 2026 | 2.34 | 2.63 | +12.4% | 65.08B | 65.63B | +0.8% |
| Q1 FY2026 | 30 Oct 2025 | 2.18 | 2.55 | +17.0% | 59.24B | 64.01B | +8.1% |
| Q4 FY2025 | 12 Aug 2025 | 2.04 | 2.08 | +2.0% | 60.89B | 60.16B | -1.2% |
| Q3 FY2025 | 1 May 2025 | 2.17 | 2.35 | +8.3% | 55.39B | 54.88B | -0.9% |
| Q2 FY2025 | 30 Jan 2025 | 1.74 | 1.93 | +10.9% | 55.02B | 55.26B | +0.4% |
| Q1 FY2025 | 1 Nov 2024 | 1.62 | 1.88 | +16.0% | 50.90B | 52.28B | +2.7% |
| Q4 FY2024 | 14 Aug 2024 | 1.73 | 1.84 | +6.4% | 58.64B | 59.87B | +2.1% |
| Q3 FY2024 | 2 May 2024 | 1.95 | 2.08 | +6.7% | 56.05B | 54.91B | -2.0% |
| Q2 FY2024 | 1 Feb 2024 | 1.60 | 1.82 | +13.7% | 57.01B | 57.45B | +0.8% |
Cardinal Health stock price 2027–2031: scenarios
If Cardinal Health's earnings keep growing at the 11.5% a year analysts expect to FY2029, it would earn about 19.37 a share in FY2031. At the P/E it has traded at over the last five years (25.9 to 75.1) that is 502.13 to 1,453.67 a share, or 783.19 at its average P/E of 40.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2027 | 12.57 | 325.93 | 508.37 | 943.57 |
| FY2028 | 14.08 | 364.91 | 569.16 | 1,056.41 |
| FY2029 | 15.59 | 404.20 | 630.45 | 1,170.17 |
| FY2030 (extrapolated) | 17.38 | 450.52 | 702.68 | 1,304.24 |
| FY2031 (extrapolated) | 19.37 | 502.13 | 783.19 | 1,453.67 |
Each year's EPS is the analysts' consensus to FY2029; the years after continue its 11.5% a year. Bear, base and bull apply the lowest, average and highest P/E of the last five fiscal year ends (25.9, 40.4, 75.1).
Is Cardinal Health stock undervalued or overvalued?
Cardinal Health's P/E of 35.0 is above the middle of its 5-year range (21.4 to 198.7, median 32.2). Analysts do not expect faster growth than in recent years, so it is expensive compared with its own history. Buyers pay about the usual price for each point of growth: a PEG of 1.2 on expected growth against 1.1 on its median P/E and past five years' growth. Growing 29.2% a year, Cardinal Health earns a P/E of 25.0 at a PEG of 1 (at most 25): × the next twelve months' EPS of 13.11, a fair value of 327.68; the price, 271.74, is 17.1% below it. Its forward P/E, on the consensus for FY2027, is 21.6.
Fair value on growth is a P/E equal to the EPS growth analysts expect a year (a PEG of 1, at most 25) times the earnings per share of the next twelve months; the ends of the bar are a PEG of 0.75 and 1.25 (a P/E of 18.8 and 31.3). The price against its P/E range
- Price to earnings ratio (TTM)
- 34.97
- Five-year median P/E
- 32.19
- Five-year P/E range
- 21.4 – 198.7
- Forward P/E (FY2027)
- 21.62
- PEG ratio
- 3.05
- To the average target
- +2.8%
Most undervalued US stocks
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 195.09146Price 99.09244 | +96.9% | |
| 186.680 | 359.93270Price 186.68450 | +92.8% | |
| 213.670 | 405.66304Price 213.67507 | +89.9% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 42.225 | 79.0244Price 42.23157 | +87.1% | |
| 160.650 | 299.85225Price 160.65375 | +86.6% | |
| 108.445 | 201.41108Price 108.45248 | +85.7% |
Furthest below the fair value on each stock's page, updated every day.